Longwood Fund

Rectify Pharmaceuticals Launches with $100 Million Series A Financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund

Retrieved on: 
Thursday, October 14, 2021
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Scripps Research, The Programme, Degenerative disease, Disease, POC, Partner, Gastrointestinal tract, Therapy, Medication, Pharma, EIF, DVI, Marshall Plan, Precision medicine, Health, Patient, ERP, Biotechnology, Computational biology, Partner (business rank), ABC, BGV, Drug discovery, Alnylam Pharmaceuticals, EUR, Vertex Pharmaceuticals, European Recovery Plan, Liver, Senior, Socially responsible investing, CBO, Department, PFM Group, Eye, Investment, Executive, Central nervous system, Vertex, CFTR, Growth, Atlas, Atlas Venture, EFSI, LFA, Cystic fibrosis, Lists of diseases, Institute of Liver and Biliary Sciences, Company, Omega, Entrepreneurship, United Nations Principles of Medical Ethics, Pharmaceutical industry, Management, Aquaculture, Fine chemical, Rectify Pharmaceuticals, Inc. (“Rectify”), Atlas Venture, Omega Funds, Forbion, Longwood Fund, RECTIFY PHARMACEUTICALS, INC. (“RECTIFY”), ATLAS VENTURE, OMEGA FUNDS, FORBION, LONGWOOD FUND

Rectify Pharmaceuticals, Inc. , (Rectify) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund.

Key Points: 
  • Rectify Pharmaceuticals, Inc. , (Rectify) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund.
  • Rectify plans to use this financing to fund the company through its first human proof-of-concept (POC) studies.
  • We founded Rectify to deliver life-changing therapies to patients with serious genetic diseases, said Rajesh Devraj, Ph.D., President and Chief Executive Officer and venture partner with Atlas Venture.
  • Jonathan Moore, Ph.D., Chief Scientific Officer, founded Rectify with Atlas Venture in 2020.